CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-NDA220106 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA220106.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated
0

Critical

0%

1

High

100%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: NDA 220106 — Type 1 - New Molecular Entity

Policy FDA-NDA220106 · Multi-specialty

High

This new molecular entity from Priovant Therapeutics (NDA220106) received Priority Review and Orphan Drug designation, but the FDA label has not yet published, leaving the drug name, route of administ

View alert

Audit documentation

Building an audit file that includes FDA-NDA220106?

The Tripwire Audit Pack exports 12 months of Multi-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Multi-specialty audit pack — $349One-time purchase · not a subscription